Panelists discuss the reimbursement of subcutaneous versus intravenous (IV) dosing and the implications for patients with multiple myeloma.
Reimbursement of Subcutaneous Versus IV Dosing in Multiple Myeloma
Panelists discuss the reimbursement of subcutaneous versus intravenous (IV) dosing and the implications for patients with multiple myeloma.
![GS twenty two - NoBoDy [lyrics Video]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_vnAMRJcRaF5SJX7bo5QZmkVJjEhOdVi4E54lktvZNB2Y57EIYhXAmt_wGQMmSnvQqaC27eY4wGkh8hQk_gMZQZhOVO69oNXqs99CkHpYEFls4-=w680)
0 Comments